Health ❯ Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials Alzheimer's Disease Monoclonal Antibodies Combination Therapy Obesity Treatments Eli Lilly Novo Nordisk GLP-1 Drugs Antibody-Drug Conjugates Weight Loss Drugs

Novartis Licenses SciNeuro’s Brain‑Shuttle Alzheimer’s Antibodies in Deal Worth Up to $1.7 Billion

Closing is targeted for the first half of 2026 pending U.S. antitrust review, reflecting a push to improve brain delivery of amyloid therapies.

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

Alveus Therapeutics Launches With $159.8 Million Series A to Advance Next‑Generation Obesity Drugs

Eupraxia Reports Early EoE Trial Data With Near‑Normal Tissue at Top Dose

FDA Grants Priority Review to Vera's Atacicept for IgA Nephropathy

Alumis TYK2 Pill Hits Phase 3 Goals in Psoriasis as Stock Jumps and $175 Million Offering Is Planned

Novo Nordisk Launches Wegovy Weight‑Loss Pill in U.S. at $149 Starter Price

Argenx Sets CEO Succession, Tapping COO Karen Massey as Tim Van Hauwermeiren Moves to Chair

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

States Curb Medicaid Coverage as First GLP‑1 Weight‑Loss Pill Debuts and Cash Prices Fall

FDA Grants Priority Review to Axsome’s AXS-05 for Alzheimer’s Agitation, Sets April 30 PDUFA Date

FDA Issues Complete Response Letter for Corcept’s Relacorilant in Cushing’s-Related Hypertension

Insilico Medicine Surges on Hong Kong Debut After HK$2.3 Billion IPO

Genmab Halts Acasunlimab to Focus on Late-Stage Cancer Portfolio

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

Neurocrine’s Valbenazine Misses Phase 3 Goals in Dyskinetic Cerebral Palsy

FDA Approves Wegovy Weight-Loss Pill as First Oral GLP-1 for Obesity

BioMarin to Acquire Amicus for $4.8 Billion in Cash

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla